Development of anticancer drug with sodium chlorite as the main pharmaceutical ingredient

Development of MA-T® system into anticancer drugs

MA-T® stands for Matching Transformation System®, an innovative oxidation control technology. By generating the required amount of active species (aqueous radicals) from chlorite ions at the required time, it is possible to inactivate viruses including epidemic viruses and sterilize various bacteria (bacteria). Moreover, for carcinoma, radicals are also produced by response to the acidic environment around the carcinoma cells, phosphatidylserine on the cell membrane, and others. HOIST has proven its hypothesis against bladder carcinoma, completed in vitro/in vivo efficacy studies, regulated safety studies, and initiated physician-initiated clinical trials.

Utilization of the MA-T® system

Antitumor effect of HM-001

Antitumor effect on orthotopic implantation model

After orthotopic implantation of UM-UC-3 cells, HM-001 was administered once/week for 4 weeks, and the tumor growth inhibition rate (% of control group) was calculated from the bladder weight.Efficacy was confirmed in the administration group of 800ppm or more.

Antitumor effect by ex-vivo exposure of HM-001

PDX (patient-derived bladder cancer Xenografted mice) cuted into 2 mm3 pieces, and exposure sodium chlorite (800, 3200, 6000ppm) at 2hrs.

After ecposure, tumor pieces were transplanted into immunodeficient mice, and then tumor volume was measured.

Anti-tumor effects were observed 800ppm or more of sodium chlorite.

ALKBH inhibitor

Developing innovative cancer treatment drugs based on epitranscriptome

The epitranscriptome is a phenomenon in which RNA, which is the transcript read out from gene expression, is modified. Part of RNA regulation by methylation is relevant to cancer biology. ALKBH is a group of enzymes that demethylate specific methylated RNAs and is highly expressed in specific cancer cells.

ALKBH3 is highly expressed in pancreatic cancer cells and linked to malignancy. Antitumor effects by inhibitors have been observed.


The PDC/PDX model has higher predictivity for human efficacy or safety than the evaluations using cancer cell lines. Therefore, research using PDC/PDX has been on the rise recently.

HOIST's PDC/PDX can be cultured immediately after cancer tissue is removed. Cells od tissues can be utilize with a small number of passages (from primary to 3 generations or less). Furthermore, since patient information is abundant, more accurate and multiple perspectives analysis is possible.

In response to requests for cells (genetic mutations, resistance to existing drugs, creation of orthotopic transplant models, etc.) from other companies, joint research and cell donation are available.